A detailed history of Janus Henderson Group PLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 122,146 shares of EXEL stock, worth $4.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
122,146
Previous 137,357 11.07%
Holding current value
$4.3 Million
Previous $3.26 Million 15.8%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$20.34 - $23.73 $309,391 - $360,957
-15,211 Reduced 11.07%
122,146 $2.74 Million
Q1 2024

May 15, 2024

SELL
$20.17 - $23.93 $2,843 - $3,374
-141 Reduced 0.1%
137,357 $3.26 Million
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $5,563 - $6,973
-289 Reduced 0.21%
137,498 $3.3 Million
Q3 2023

Nov 14, 2023

SELL
$19.04 - $22.74 $799 - $955
-42 Reduced 0.03%
137,787 $3.01 Million
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $2,870 - $3,235
-158 Reduced 0.11%
137,829 $2.63 Million
Q1 2023

May 15, 2023

SELL
$16.3 - $19.41 $1.2 Million - $1.43 Million
-73,456 Reduced 34.74%
137,987 $2.68 Million
Q4 2022

Feb 14, 2023

SELL
$14.96 - $17.39 $9.38 Million - $10.9 Million
-627,210 Reduced 74.79%
211,443 $3.39 Million
Q3 2022

Nov 14, 2022

SELL
$15.68 - $22.27 $3.77 Million - $5.35 Million
-240,265 Reduced 22.27%
838,653 $13.2 Million
Q2 2022

Aug 15, 2022

SELL
$17.44 - $23.16 $9.1 Million - $12.1 Million
-521,711 Reduced 32.59%
1,078,918 $22.5 Million
Q1 2022

May 16, 2022

SELL
$17.03 - $22.67 $6.81 Million - $9.07 Million
-399,973 Reduced 19.99%
1,600,629 $36.3 Million
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $2.59 Million - $3.58 Million
163,416 Added 8.89%
2,000,602 $36.6 Million
Q3 2021

Nov 16, 2021

BUY
$16.3 - $21.14 $29.9 Million - $38.8 Million
1,837,186 New
1,837,186 $38.8 Million
Q1 2021

May 17, 2021

SELL
$20.53 - $25.22 $17.9 Million - $22 Million
-874,031 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$18.39 - $24.8 $65 Million - $87.7 Million
-3,536,063 Reduced 80.18%
874,031 $17.5 Million
Q3 2020

Nov 16, 2020

SELL
$20.67 - $26.94 $18.5 Million - $24.1 Million
-893,989 Reduced 16.85%
4,410,094 $108 Million
Q2 2020

Aug 14, 2020

BUY
$16.46 - $27.42 $27.8 Million - $46.3 Million
1,689,992 Added 46.76%
5,304,083 $126 Million
Q1 2020

May 14, 2020

BUY
$14.46 - $21.8 $51.7 Million - $78 Million
3,575,955 Added 9376.85%
3,614,091 $62.2 Million
Q4 2019

Feb 18, 2020

SELL
$15.15 - $18.89 $177,527 - $221,353
-11,718 Reduced 23.5%
38,136 $672,000
Q3 2019

Nov 14, 2019

SELL
$17.68 - $22.65 $1.95 Million - $2.49 Million
-110,112 Reduced 68.83%
49,854 $881,000
Q2 2019

Jul 31, 2019

BUY
$18.93 - $24.75 $2.41 Million - $3.15 Million
127,372 Added 390.78%
159,966 $3.42 Million
Q1 2019

Apr 30, 2019

BUY
$19.6 - $24.76 $638,842 - $807,027
32,594 New
32,594 $776,000
Q2 2018

Aug 10, 2018

SELL
$18.56 - $22.45 $1.12 Million - $1.36 Million
-60,400 Closed
0 $0
Q1 2018

May 14, 2018

SELL
$22.15 - $31.89 $646,780 - $931,188
-29,200 Reduced 32.59%
60,400 $1.34 Million
Q4 2017

Feb 09, 2018

SELL
$24.23 - $30.93 $25.1 Million - $32.1 Million
-1,037,692 Reduced 92.05%
89,600 $2.72 Million
Q3 2017

Nov 14, 2017

SELL
$23.35 - $29.24 $875,765 - $1.1 Million
-37,506 Reduced 3.22%
1,127,292 $0
Q2 2017

Aug 17, 2017

BUY
N/A
1,164,798
1,164,798 $28.7 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.3B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.